NPHC — Nutra Pharma Share Price
Last trade - 00:00- $0.76m
- $8.85m
- $0.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -592.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.12 | 0.13 | 0.1 | 0.05 | 0.1 | n/a | n/a | -10.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nutra Pharma Corp. is a holding company, which owns intellectual property and operates in the biotechnology industry. The Company conducts drug discovery research and development activities on its own and through its subsidiary, ReceptoPharm, Inc. Its first consumer product, Cobroxin, is an over-the-counter pain reliever designed to treat moderate to severe chronic pain. Its second consumer product, Nyloxin, is an over-the-counter pain reliever that is a stronger version of Cobroxin and is designed to treat severe chronic pain. Pet Pain-Away is an over-the-counter pain reliever designed to treat pain in cats and dogs. Equine Pain-Away is an over-the-counter topical pain reliever designed to treat pain and inflammation in horses. Its Luxury Feet is an over-the-counter pain reliever designed specifically to treat foot pain and inflammation, especially for women who wear high heels and stilettos. The Company also manufactures Cell Defender, ZMUNITY, and Avini Plus Energy, among others.
Directors
- Rik Deitsch CHM (47)
- Dale Vanderputten CSO (57)
- Stewart Lonky DRC (68)
- Garry Pottruck DRC (58)
- Harold Rumph DRC (84)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- February 1st, 2000
- Public Since
- October 9th, 2001
- No. of Shareholders
- 288
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 7,596,852,214
- Address
- 1537 NW 65th Avenue, PLANTATION, 33313
- Web
- https://www.nutrapharma.com/
- Phone
- +1 9545090911
- Auditors
- Rotenberg Meril Solomon Bertiger & Guttilla, P.C.
Upcoming Events for NPHC
Similar to NPHC
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 22:26 UTC, shares in Nutra Pharma are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Nutra Pharma last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Nutra Pharma share price has underperformed the S&P500 Index by -16.07% over the past year.
There is no consensus recommendation for this security.
Nutra Pharma does not currently pay a dividend.
Nutra Pharma does not currently pay a dividend.
Nutra Pharma does not currently pay a dividend.
To buy shares in Nutra Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Nutra Pharma had a market capitalisation of $0.76m.
Here are the trading details for Nutra Pharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NPHC
Based on an overall assessment of its quality, value and momentum Nutra Pharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nutra Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +8955.66%.
As of the last closing price of $0.00, shares in Nutra Pharma were trading -49.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nutra Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nutra Pharma's management team is headed by:
- Rik Deitsch - CHM
- Dale Vanderputten - CSO
- Stewart Lonky - DRC
- Garry Pottruck - DRC
- Harold Rumph - DRC